Meduni Vienna: New imaging method shows promising results in the early detection of pulmonary complications in myositis
In a multidisciplinary collaboration, a research team from the Medical University of Vienna and Univdersity Hospital Vienna has demonstrated that a novel imaging technique could predict the progression of severe pulmonary complications in patients with rare autoimmune muscle diseases at an early stage. The study, recently published in the Journal of Autoimmunity, shows that FAPI-PET/CT – a method for visualising scarring and inflammation in lung tissue – is more sensitive than conventional methods. This could represent an important step towards more precise risk assessment and more individualised treatment of interstitial lung disease (ILD) in myositis.
Interstitial lung disease (ILD) is one of the most dangerous complications of myositis (an autoimmune inflammation of the skeletal muscles) and often leads to shortness of breath, frequent hospitalisations and premature mortality. It is difficult to identify which patients will experience a deterioration in their condition, as the tests currently available often only indicate changes once lung damage has already occurred.
The joint study by researchers from the Division of Rheumatology in collaboration with the Division of Nuclear Medicine and the Division of General and Paediatric Radiology at MedUni Vienna and University Hospital Vienna shows that FAPI-PET/CT, an imaging technique that visualises scarring and inflammation in the lungs, can predict the course of the disease. In a two-year study involving 14 patients, those with higher uptake of the FAPI tracer at the start of the study were more likely to experience worsening ILD, require more intensive treatment or need hospitalisation.
"With this imaging technique, we can visualise lung scarring before extensive and irreversible damage occurs," says Peter Mandl, lead author of the study from the Division of Rheumatology (Department of Medicine III) at MedUni Vienna and University Hospital Vienna. "As a supportive tool for risk assessment – in addition to established standard examinations – FAPI-PET/CT can help to identify high-risk patients earlier and, if necessary, tailor therapies more individually."
The authors point out that the results need to be confirmed in larger studies, but see FAPI-PET/CT as a possible step towards precision medicine for ILD.
Contact
Medizinische Universität Wien
Mag. Johannes Angerer
Leiter Kommunikation und
Öffentlichkeitsarbeit
Tel.: 01/ 40 160 11 501
E-Mail: pr@meduniwien.ac.at
Spitalgasse 23, 1090 Wien
www.meduniwien.ac.at/
Universitätsklinikum AKH Wien
Karin Fehringer, MBA MSc
Leiterin Informationszentrum und PR
Wiener Gesundheitsverbund
Tel.: +43 1 404 00-12160
E-Mail: presse@akhwien.at
Währinger Gürtel 18-20, 1090 Wien
www.akhwien.at/presse